IL-21R-Targeted Nano-immunosuppressant Prevents Acute Rejection in Allogeneic Transplantation by Blocking Maturation of T Follicular Helper Cells
Acta Biomaterialia · 2025
DOI: 10.1016/j.actbio.2025.05.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2025. Verfasst von Xiandong Zeng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery and Liver Transplantation, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Graft Rejection, Immunosuppressive Agents, Receptors, Interleukin-21, T Follicular Helper Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Municipal Natural Science Foundation.
Abstract (Originalsprache)
During organ transplantation, immune rejection is a primary cause of graft failure. In the underlying pathophysiology of rejection, T follicular helper (Tfh) cells and interleukin-21 (IL-21) play pivotal roles. Tfh cells exacerbate the humoral immune response by promoting B cell differentiation and antibody production, which leads to damage of the transplanted tissue. IL-21, a key pro-inflammatory cytokine, binds to its receptor (IL-21R) to enhance both the growth and function of Tfh cells, while also further driving B cell activation and differentiation into plasma cells. Building on this knowledge, we have developed a tacrolimus-based nano-inhibitor designed to target Tfh cells. This nano-inhibitor is constructed using a mPEG-PLGA-PLL (PEAL) scaffold, with IL-21R monoclonal antibodies conjugated to its surface, and tacrolimus encapsulated within the structure. In vitro experiments demonstrated that this nano-inhibitor effectively targets Tfh cells, inhibiting the differentiation of naive CD4+ T cells into Tfh cells. In co-culture systems of T and B cells, it significantly suppresses the activation of both cell types, leading to a reduction in IgG antibody production. In vivo, the nano-inhibitor selectively targets secondary lymphoid organs, reduces systemic inflammation, minimizes lymphocyte infiltration into the graft, and induces immune tolerance toward the transplanted tissue. In addition, no significant toxicity was observed in vitro or in vivo. As a therapeutic agent that simultaneously modulates both T and B cell responses, we believe it holds significant promise for broader applications in transplantation immunotherapy. STATEMENT OF SIGNIFICANCE: This study presents a groundbreaking nano-immunosuppressant designed to target both T and B cells, addressing the critical challenge of acute rejection in allogeneic transplantation. By combining tacrolimus nanoparticles with IL-21 receptor antibodies, this immunosuppressant effectively suppresses Tfh cell proliferation and B cell activation, significantly reducing IgG generation. The formulation enhances tacrolimus's bioavailability, minimizes off-target toxicity, and overcomes its narrow therapeutic window. In vitro and in vivo studies show reduced lymphocyte infiltration, lower inflammatory markers, and decreased nephrotoxicity compared to conventional tacrolimus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Surgery and Liver Transplantation, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200032, China.
- School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, PR China.
- Department of Liver Surgery and Liver Transplantation, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: xiaqiang@shsmu.edu.cn.
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200032, China. Electronic address: yrduan@shsci.org.
- Department of Liver Surgery and Liver Transplantation, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: hekang@renji.com.
Förderung
- Shanghai Municipal Natural Science Foundation
Zitieren
APA
Zeng, X., Pan, Y., Lin, J., Zheng, Z., Wu, H., Wang, Y., Wu, Y., Shen, Y., Chen, Y., Zhao, Y., Xia, Q., Duan, Y., & He, K. (2025). IL-21R-Targeted Nano-immunosuppressant Prevents Acute Rejection in Allogeneic Transplantation by Blocking Maturation of T Follicular Helper Cells. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2025.05.012
Vancouver
Zeng X, Pan Y, Lin J, Zheng Z, Wu H, Wang Y, et al. IL-21R-Targeted Nano-immunosuppressant Prevents Acute Rejection in Allogeneic Transplantation by Blocking Maturation of T Follicular Helper Cells. Acta Biomaterialia. 2025. doi:10.1016/j.actbio.2025.05.012
BibTeX
@article{Zeng2025,
author = {Zeng, Xiandong and Pan, Yixiao and Lin, Jiangtao and Zheng, Zhigang and Wu, Huimin and Wang, Yining and Wu, You and Shen, Yufei and Chen, Yujia and Zhao, Yifan and Xia, Qiang and Duan, Yourong and He, Kang},
title = {IL-21R-Targeted Nano-immunosuppressant Prevents Acute Rejection in Allogeneic Transplantation by Blocking Maturation of T Follicular Helper Cells},
journal = {Acta Biomaterialia},
year = {2025},
doi = {10.1016/j.actbio.2025.05.012}
}
EUVIMED